43rd Annual Miami Breast Cancer Conference® - Abstracts

This literature review and institutional case report describes primary NECB with synchronous pancreatic and liver metastases as an extraordinarily rare, aggressive phenotype requiring multidisciplinary management driven by tumor biology rather than surgery.

In 42 patients with DCIS undergoing breast-conserving surgery, 71.4% had detectable disseminated cancer cells in bone marrow, with residual-risk DCISionRT score significantly correlated with higher DCC burden compared with low- and elevated-risk groups.

In a retrospective multi-institution study of 267 early-stage breast cancer patients, the TumorSight Viz AI algorithm achieved landmark identification and measurement accuracy comparable to inter-radiologist variability, generating results in an average of 8 minutes per patient.

Routine intraoperative frozen section analysis of sentinel lymph nodes after neoadjuvant chemotherapy did not improve surgical outcomes and led to unnecessary axillary lymph node dissection in over half of intraoperatively positive cases.

In this prospective multicenter study, the next-generation MarginProbe device (MP2) achieved sensitivity of 76.8% and specificity of 49.1% for intraoperative lumpectomy margin assessment, meeting all predefined success criteria and earning FDA approval in September 2025.

PREDICT II is a prospective 30-site observational registry enrolling 3000 women with DCIS to evaluate how a 7-gene biosignature (DCISionRT) impacts treatment recommendations for surgery, radiation, and hormonal therapy.

In this randomized trial, adding a pictorial COPE photo guide to standard verbal counseling for breast cancer patients receiving adjuvant RT led to the only statistically significant improvement in post-treatment skin change scores, with modest non-significant trends toward reduced anxiety.

This narrative review summarizes existing literature and clinical trial data on metastasis-directed and locoregional therapy for oligometastatic and oligoprogressive metastatic breast cancer, highlighting special scenarios where MDT may improve outcomes.